

CITATION REPORT

List of articles citing

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

DOI: 10.1007/bf01518520

Cancer Immunology, Immunotherapy, 1993, 37, 255-63.

Source: <https://exaly.com/paper-pdf/23962530/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
429	Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells. 1992 , 33, 1107		
428	Receptor blockade with monoclonal antibodies as anti-cancer therapy. 1994 , 64, 127-54		75
427	Prolonged survival of mice with human gastric cancer treated with an anti-c-ErbB-2 monoclonal antibody. 1995 , 71, 969-73		27
426	Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab) ₂ for efficient lysis of p185HER2 overexpressing tumor cells. 1995 , 62, 319-24		41
425	Axon-induced mitogenesis of human Schwann cells involves heregulin and p185erbB2. 1995 , 92, 1431-5		249
424	Development of anti-p185HER2 immunoliposomes for cancer therapy. 1995 , 92, 1327-31		232
423	Inhibition of erbB-2-positive breast cancer cell growth by erbB-2 antisense oligonucleotides. 1996 , 6, 9-16		22
422	BRCA1 protein products: antibody specificity. 1996 , 13, 264-5		55
421	Targeting of Liposomes to Solid Tumors: The Case of Sterically Stabilized Anti-Her2 Immunoliposomes. 1997 , 7, 391-417		25
420	Immunoliposomes for cancer treatment. 1997 , 40, 399-435		78
419	Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. 1997 , 36, 66-75		374
418	Inducible antisense inhibition of erbB-2 expression reduces anchorage independent growth of ovarian carcinoma cells. 1997 , 117, 73-9		7
417	Anti-HER2 immunoliposomes for targeted therapy of human tumors. 1997 , 118, 153-60		103
416	Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b. 1997 , 14, 1-16		178
415	Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175. 1997 , 15, 1385-94		83
414	Type I receptor tyrosine kinases as targets for therapy in breast cancer. 1997 , 2, 165-74		18
413	Heregulins and the ErbB-2/3/4 receptors in gliomas. 1997 , 35, 335-46		25

412	Specific cytotoxic T lymphocytes in gene therapy. 1997 , 75, 259-66	32
411	Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale. <i>Cancer Immunology, Immunotherapy</i> , 1997 , 45, 1-9	7-4 93
410	HER-2/neu signal transduction in human breast and ovarian cancer. 1997 , 15, 1-8	156
409	Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro. 1997 , 73, 875-9	48
408	Constitutively tyrosine phosphorylated p52 Shc in breast cancer cells: correlation with ErbB2 and p66 Shc expression. 1998 , 49, 119-28	33
407	HER-2/neu as a predictive marker of response to breast cancer therapy. 1998 , 52, 65-77	210
406	Human tumor growth suppression by apoptosis induced with anti-ErbB-2 chimeric monoclonal antibody. 1998 , 89, 562-70	8
405	An efficient route to human bispecific IgG. 1998 , 16, 677-81	312
404	Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu. 1998 , 77, 85-90	19
403	Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides. 1998 , 273, 15621-7	155
402	Therapeutic Applications of Ribozymes. 1998 ,	8
401	Editorial. 1998 , 11, 1-1	
400	Targeting of Drugs to Solid Tumors Using Anti-Her2 Immunoliposomes. 1998 , 8, 425-442	18
399	Anti-c-erb-B-2 Ribozyme for Breast Cancer. 1998 , 223-240	1
398	Herceptin: breaking new ground. 1999 , 14, 1-4	6
397	Kinase receptor activation (KIRA): a rapid and accurate alternative to end-point bioassays. 1999 , 19, 883-91	52
396	Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. 1999 , 18, 731-8	116
395	The ErbB receptors as targets for breast cancer therapy. 1999 , 4, 337-51	20

394	Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family. 1999 , 58, 41-56	40
393	Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy. 1999 , 5, 255-71	47
392	Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazoliny]-2-butynamide (CL-387,785). 1999 , 57, 917-25	88
391	Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. 1999 , 27, 1533-41	164
390	Trastuzumab: a viewpoint by Mark Pegram. 1999 , 12, 136-8	0
389	Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. 1999 , 21, 309-18	344
388	Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents. 1999 , 126, 413-421	19
387	Targeted gene delivery to mammalian cells by filamentous bacteriophage. 1999 , 288, 203-11	143
386	Toward selection of internalizing antibodies from phage libraries. 1999 , 255, 386-93	143
385	Heregulin regulation of Akt/protein kinase B in breast cancer cells. 1999 , 261, 897-903	59
384	Emerging antibody-based HER2 (ErbB-2/neu) therapeutics. 2000 , 11, 113-24	18
383	Development of herceptin. 2000 , 11, 103-11	23
382	Role of HER2 gene overexpression in breast carcinoma. 2000 , 182, 150-62	218
381	Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. 2000 , 6, 443-6	2222
380	Combinatorial chemoprevention of intestinal neoplasia. 2000 , 6, 1024-8	452
379	Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells. 2000 , 7, 241-8	55
378	The EGF receptor family as targets for cancer therapy. 2000 , 19, 6550-65	1132
377	Autoimmune and antitumor consequences of antibodies against antigens shared by normal and malignant tissues. 2000 , 20, 85-93	22

376	The ErbB signaling network: receptor heterodimerization in development and cancer. 2000 , 19, 3159-67	1806
375	Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. 2000 , 18, 3651-64	553
374	p185HER2 overexpression in human breast cancer using molecular and immunohistochemical methods. 2000 , 18, 336-42	18
373	ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. 2000 , 20, 3210-23	247
372	Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells. 2000 , 92, 987-94	24
371	Gene Therapy of Cancer. 2000 ,	1
370	The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. 2000 , 103, 57-75	157
369	Selection of tumor-specific internalizing human antibodies from phage libraries. 2000 , 301, 1149-61	183
368	Herceptin: increasing survival in metastatic breast cancer. 2000 , 4, 24-9	18
367	Tyrosine kinase signalling in breast cancer. 2000 , 2, 154-7	57
366	Biological Therapy of Breast Cancer. 2000 , 14, 221-246	7
365	Anti-c-erbB2 Ribozyme for Gene Therapy of Breast Cancer. 2000 , 35, 247-60	
364	Liposome targeting to tumors using vitamin and growth factor receptors. 2000 , 60, 285-332	41
363	Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5. 2000 , 11, 327-34	31
362	Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2. 2000 , 82, 46-51	59
361	Anti-HER2 therapy: how to use Herceptin in clinical practice. 2000 , 4, 30-6	1
360	The biology of natural killer cells and implications for therapy of human disease. 2001 , 10, 451-63	27
359	Clinical trials of Herceptin [®] (trastuzumab). 2001 , 37, 18-24	144

358	First-line, single-agent Herceptin [®] (trastuzumab) in metastatic breast cancer. 2001 , 37, 25-29	128
357	HER2: the neu prognostic marker for breast cancer. 2001 , 38, 167-82	8
356	Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. 2001 , 12 Suppl 1, S21-2	76
355	Mechanism of action of anti-HER2 monoclonal antibodies. 2001 , 12 Suppl 1, S35-41	139
354	Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. 2001 , 19, 354-63	273
353	Herceptin: from the bench to the clinic. 2001 , 19, 49-56	42
352	Biological and clinical significance of HER2 overexpression in breast cancer. 2001 , 8, 45-51	39
351	Evaluation of HER2 status: for the treatment of metastatic breast cancers by humanized anti-HER2 Monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab). 2001 , 8, 316-20	11
350	Gastric cancer cell lines as models to study human digestive functions. 2001 , 81, 241-251	44
349	Involvement of ErbB-2 in rheumatoid synovial cell growth. 2001 , 44, 260-5	44
348	Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. 2001 , 31, 3016-25	129
347	DNA strand breaks and cell cycle perturbation in herceptin treated breast cancer cell lines. 2001 , 70, 123-9	26
346	Tumor targeting using anti-her2 immunoliposomes. 2001 , 74, 95-113	279
345	Bispecific human IgG by design. 2001 , 248, 7-15	139
344	The biology of natural killer cells in cancer, infection, and pregnancy. 2001 , 29, 1157-68	105
343	Targeting HER2 in other tumor types. 2001 , 12 Suppl 1, S81-7	108
342	Trastuzumab in the treatment of HER2 positive breast cancer. 2001 , 7, 9-25	1
341	Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. 2001 , 61 Suppl 2, 14-21	164

340	Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe. 2001 , 12 Suppl 1, S89-94	17
339	Phase I and II clinical trials of trastuzumab. 2001 , 12 Suppl 1, S49-55	53
338	First-line Herceptin monotherapy in metastatic breast cancer. 2001 , 61 Suppl 2, 37-42	164
337	Monoclonal antibody therapy. 2001 , 56, 369-421	9
336	Biology of natural killer cells in cancer and infection. 2002 , 20, 405-19	50
335	Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. 2002 , 13, 65-72	197
334	[Immunohistochemical research on breast cancer cell proliferation and hormonal receptor status with special emphasis on HER-2/neu expression]. 2002 , 124, 473-7	
333	Novel targets for lung cancer therapy: part I. 2002 , 20, 2881-94	108
332	TUMOR ANTIGENS AS TARGETS FOR ANTICANCER DRUG DEVELOPMENT. 2002 , 157-170	2
331	Pathological Evaluation of HER2 Overexpression: For the Treatment of Metastatic Breast Cancers by Humanized Anti-HER2 Monoclonal Antibody(Trastuzumab).. 2002 , 35, 77-81	3
330	Applications of advances in molecular biology and genomics to clinical cancer care. 2002 , 25, 110-22; quiz 123-4	5
329	In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines. 2002 , 13, 1743-8	59
328	The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. 2002 , 3, 125-35; discussion 136-7	65
327	Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. 2002 , 37, 17-27	26
326	Trastuzumab: hopes and realities. 2002 , 3, 137-44	134
325	Efficacy of vaccination with plasmid DNA encoding for HER2/neu or HER2/neu-eGFP fusion protein against prostate cancer in rats. 2002 , 2, 783-96	14
324	The future of targeted therapy: combining novel agents. 2002 , 63 Suppl 1, 47-56	21
323	Molecular targets in cancer therapy and their impact on cancer management. 2002 , 63 Suppl 1, 1-5	8

322	Trastuzumab in the treatment of non-small cell lung cancer. 2002 , 29, 59-65	33
321	HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. 2002 , 29, 4-10	7
320	Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. 2002 , 1591, 109-118	137
319	Signaling revealed by mapping molecular interactions. 2002 , 2, 169-186	11
318	HER2/neu in the management of invasive breast cancer. 2002 , 194, 488-501	33
317	Prognostic and predictive value of HER2/neu oncogene in breast cancer. 2002 , 59, 102-8	63
316	Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. 2002 , 99, 783-91	153
315	HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity. 2002 , 94, 415-20	34
314	HER-2 in breast cancer--methods of detection, clinical significance and future prospects for treatment. 2002 , 43, 231-44	26
313	Gamma-heregulin has no biological significance in primary breast cancer. 2002 , 86, 1362-3	6
312	Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. 2003 , 21, 283-90	499
311	Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu. 2003 , 107, 976-83	40
310	Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. 2003 , 46 Suppl, S85-104	98
309	Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. 2003 , 22, 6629-38	80
308	Primer on medical genomics. Part VI: Genomics and molecular genetics in clinical practice. 2003 , 78, 307-17	20
307	The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. 2003 , 278, 3466-73	1018
306	Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. 2003 , 21, 2787-99	1051
305	HER2-Positive Breast Cancer. 2003 , 2, 169-179	4

304	Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. 2003 , 532, 253-68	149
303	Design, construction, and in vitro analyses of multivalent antibodies. 2003 , 170, 4854-61	49
302	Signal transduction--directed cancer treatments. 2003 , 43, 199-231	76
301	A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. 2003 , 170, 4242-53	59
300	The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair. 2003 , 278, 20582-92	129
299	Development of HER2-specific humanized antibody Herceptin (trastuzumab). 2003 , 122, 504-14	2
298	. 2003 ,	21
297	Principles of Molecular Oncology. 2004 ,	6
296	Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. 2004 , 10, 4489-97	75
295	Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. 2004 , 64, 2127-33	277
294	Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. 2004 , 10, 2512-24	72
293	Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. 2004 , 64, 3958-65	493
292	Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. 2004 , 10, 3885-96	142
291	Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. 2004 , 64, 2601-9	86
290	Synergistic interactions between tamoxifen and trastuzumab (Herceptin). 2004 , 10, 1409-20	68
289	Recombinant humanised anti-HER2/neu antibody (Herceptin) induces cellular death of glioblastomas. 2004 , 91, 1195-9	45
288	Cellular Drug Delivery. 2004 ,	5
287	HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. 2004 , 10, 2499-511	89

286	Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine. 2004 , 97, 357-69	124
285	Future directions of liposome- and immunoliposome-based cancer therapeutics. 2004 , 31, 196-205	190
284	Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?. 2004 , 5, 525-31	82
283	Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma. 2004 , 86, 125-37	40
282	Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. 2004 , 88, 901-8	142
281	Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells. 2004 , 109, 291-301	36
280	Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells. 2004 , 112, 492-501	42
279	The role of targeted therapy in non-small cell lung cancer. 2004 , 51, 29-44	21
278	Clinical cardiac tolerability of trastuzumab. 2004 , 22, 322-9	224
277	Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. 2004 ,	
276	Individualization of Drug Regimens: Integration of Pharmacokinetic and Pharmacogenetic Principles in Drug Therapy. 2004 , 381-400	
275	Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. 2004 , 12, 461-71	167
274	Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. 2004 , 212, 167-75	248
273	Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. 2004 , 214, 215-24	59
272	New dual inhibitors of EGFR and HER2 protein tyrosine kinases. 2005 , 15, 4774-9	39
271	FLT3 antibody-based therapeutics for leukemia therapy. 2005 , 82, 108-14	5
270	Trastuzumab (Herceptin) in metastatic transitional cell carcinoma of the urinary tract: report on six patients. 2005 , 48, 771-5; discussion 775-8	24
269	Cyclin E as a prognostic and predictive marker in breast cancer. 2005 , 15, 319-26	51

268	Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. 2005 , 116, 359-67	115
267	Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors. 2005 , 91, 187-201	73
266	Monoclonal Antibody Strategies for Targeting HER2. 2005 , 627-645	
265	Antiangiogenic Steroids in Human Cancer Therapy. 2005 , 2, 49-57	41
264	Targeting of the EGFR As a Modulator of Cancer Chemotherapy. 2005 , 1-26	2
263	Low levels of Her2/neu expressed by Ewing β family tumor cell lines can redirect cytokine-induced killer cells. 2005 , 11, 4561-70	27
262	In vitro cytotoxicity of carcinoma cells with ¹¹¹ In-labeled antibodies to HER-2. 2005 , 4, 927-37	17
261	Protein Therapeutics. 2005 , 429-446	
260	Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. 2005 , 65, 3781-7	169
259	Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates. 2005 , 65, 6371-9	74
258	Medical Biomethods Handbook. 2005 ,	2
257	Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. 2005 , 11, 2327-36	156
256	Docetaxel/trastuzumab combination therapy for the treatment of breast cancer. 2005 , 6, 1555-64	13
255	Receptor-targeted cancer therapy. 2005 , 24, 271-82	27
254	Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol. 2005 , 16, 1117-25	29
253	Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu--a new method of epitope definition. 2005 , 42, 1121-4	31
252	Antitumor activity of HER-2 inhibitors. 2005 , 227, 9-23	77
251	The antitumor immune response in HER-2 positive, metastatic breast cancer patients. 2005 , 3, 13	6

250	Trastuzumab in the treatment of breast cancer. 2005 , 353, 1734-6	227
249	Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways. 2006 , 8, R35	25
248	Biomarkers in Breast Cancer. 2006 ,	3
247	Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. 2006 , 3, 269-80	756
246	Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to Fcγ3R. 2006 , 12, 2879-87	180
245	Trastuzumab (Herceptin) for Ductal Carcinoma in Situ of the Breast. 2006 , 17, 122-125	
244	Trastuzumab-polyethylenimine-polyethylene glycol conjugates for targeting Her2-expressing tumors. 2006 , 17, 1190-9	61
243	Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. 2006 , 66, 6732-40	910
242	Herceptin: mechanisms of action and resistance. 2006 , 232, 123-38	353
241	High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. 2006 , 43, 1183-93	109
240	In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. 2006 , 33, 333-47	47
239	Epidermal growth factor receptor pathway inhibitors. 2006 , 1, 299-310	5
238	Antibody Therapy for Solid Tumors. 2006 , 433-444	
237	Cancer. 2006 ,	
236	erb-B2 as a Therapeutic Target. 2006 , 159-175	1
235	A phosphoproteomic analysis of the ErbB2 receptor tyrosine kinase signaling pathways. 2006 , 45, 15529-40	44
234	The Fc portion of UV3, an anti-CD54 monoclonal antibody, is critical for its antitumor activity in SCID mice with human multiple myeloma or lymphoma cell lines. 2006 , 29, 489-98	13
233	HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. 2006 , 16, 1897-902	102

232	HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays. 2006 , 48, 149-56	36
231	From glycomics to functional glycomics of sugar chains: Identification of target proteins with functional changes using gene targeting mice and knock down cells of FUT8 as examples. 2006 , 1764, 1881-9	22
230	Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. 2006 , 6, 1161-73	140
229	Targeting of solid tumors and blood malignancies by antibody-based therapies ÆGFR-pathway as an example. 2006 , 1, 167-182	6
228	Monoclonal and bispecific antibodies as novel therapeutics. 2006 , 54, 85-101	25
227	Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC. 2006 , 94, 680-8	110
226	Development of antibody-based therapeutics for oncology indications. 2006 , 67, 699-728	2
225	RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes. 2006 , 45, 761-9	91
224	Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab. 2006 , 5, 648-56	47
223	Development of antibodies and chimeric molecules for cancer immunotherapy. 2006 , 90, 83-131	36
222	PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells. 2006 , 12, 4192-9	33
221	Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. 2006 , 5, 665-75	86
220	Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib. 2006 , 66, 7708-15	34
219	Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. 2006 , 12, 4925-32	78
218	Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. 2006 , 6, 455-89	28
217	A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. 2007 , 13, 1875-82	92
216	Targeted therapies for non-small cell lung cancer. 2007 , 13, 2810-31	13
215	AKT1, AKT2 and AKT3-dependent cell survival is cell line-specific and knockdown of all three isoforms selectively induces apoptosis in 20 human tumor cell lines. 2007 , 6, 755-62	62

214	Regression of experimental medulloblastoma following transfer of HER2-specific T cells. 2007 , 67, 5957-64	136
213	Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor. 2007 , 67, 9887-93	46
212	Current treatment and clinical trial developments for ductal carcinoma in situ of the breast. 2007 , 12, 1276-87	51
211	Assessment of a new anti-HER2 monoclonal antibody, SV2-61gamma: a best concordance with HER2 FISH. 2007 , 15, 389-93	5
210	Current immunotherapeutic strategies in breast cancer. 2007 , 16, 841-60, ix	4
209	Breast Cancer Chemosensitivity. 2007 ,	2
208	Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. 2007 , 18, 977-84	406
207	Monoclonal antibody-based therapeutics for leukemia. 2007 , 7, 319-30	18
206	Overview of resistance to systemic therapy in patients with breast cancer. 2007 , 608, 1-22	596
205	HER2 testing: a review of detection methodologies and their clinical performance. 2007 , 7, 53-64	34
204	ErbB receptors: from oncogenes to targeted cancer therapies. 2007 , 117, 2051-8	396
203	Multiparameter noninvasive assessment of treatment susceptibility, drug target inhibition and tumor response guides cancer treatment. 2007 , 121, 2492-500	12
202	Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. 2007 , 28, 1565-71	258
201	Targeting the function of the HER2 oncogene in human cancer therapeutics. 2007 , 26, 6577-92	148
200	Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin). 2007 , 13, 72-5	19
199	Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives. 2007 , 28, 1476-93	38
198	Dissecting kinase signaling pathways. 2007 , 12, 717-24	13
197	Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. 2007 , 120, 169-77	195

196	Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. 2007 , 59, 795-805	146
195	Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies. 2007 , 55, 109-14	76
194	Mimotope vaccines: epitope mimics induce anti-cancer antibodies. 2007 , 113, 1-5	36
193	Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. 2008 , 99, 1415-25	104
192	Adjuvant trastuzumab therapy for HER2-positive breast cancer. 2008 , 8, 324-33	57
191	Unraveling the biologic and clinical complexities of HER2. 2008 , 8, 392-401	77
190	Signal-Transduction Therapy. 2008 , 226, 1-13	1
189	Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. 2008 , 1785, 232-65	113
188	Herceptin. 2008 , 183-219	52
187	Tetrazine-based cycloadditions: application to pretargeted live cell imaging. 2008 , 19, 2297-9	584
186	HER2 targeted polyplexes: the effect of polyplex composition and conjugation chemistry on in vitro and in vivo characteristics. 2008 , 19, 244-53	15
185	Human breast cancer tumor models: molecular imaging of drug susceptibility and dosing during HER2/neu-targeted therapy. 2008 , 248, 925-35	53
184	The tyrphostin B42 inhibits cell proliferation and HER-2 autophosphorylation in cervical carcinoma cell lines. 2008 , 26, 136-44	7
183	Challenges in Combinational Oncology Studies. 2008 , 22, 85-97	3
182	Complement and cellular cytotoxicity in antibody therapy of cancer. 2008 , 8, 759-68	64
181	Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. 2008 , 68, 9280-90	1193
180	Prognostic and Predictive Factors in Breast Cancer. 2008 ,	1
179	Of mice and (wo)men: is this any way to test a new drug?. 2008 , 26, 830-2	16

178	Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity. 2008 , 14, 1192-9	16
177	Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC. <i>Drug Design, Development and Therapy</i> , 2008 , 7	4-4 14
176	The epidermal growth factor receptor family in breast cancer. 2008 , 1, 5-19	18
175	Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines. 2009 , 15, 7196-206	42
174	The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. 2009 , 69, 4270-6	74
173	Immunological Approaches in the Treatment of Metastasized Breast Cancer. 2009 , 4, 359-366	10
172	¹¹¹ In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1. 2009 , 24, 163-73	12
171	Applications for site-directed molecular imaging agents coupled with drug delivery potential. 2009 , 6, 745-68	24
170	Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer. 2009 , 5, 135-47	3
169	Ductal carcinoma in situ: state of the science and roadmap to advance the field. 2009 , 27, 279-88	115
168	Effective incorporation of biomarkers into phase II trials. 2009 , 15, 1898-905	67
167	Modification of HER2 pre-mRNA alternative splicing and its effects on breast cancer cells. 2009 , 124, 772-7	31
166	Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies. 2009 , 11, 156-62	17
165	Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective. 2009 , 85, 535-8	16
164	Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. 2009 , 9, 463-75	881
163	Core fucose and bisecting GlcNAc, the direct modifiers of the N-glycan core: their functions and target proteins. 2009 , 344, 1387-90	172
162	Development of different analysis platforms with LC-MS for pharmacokinetic studies of protein drugs. 2009 , 81, 8715-23	64
161	Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. 2009 , 27, 5838-47	372

160	Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care. 2010 , 33, 186-95	51
159	Feasibility of tailored, selective and effective anticancer chemotherapy by direct injection of docetaxel-loaded immunoliposomes into Her2/neu positive gastric tumor xenografts. 2010 , 38,	
158	Multiplexed Five-Color Molecular Imaging of Cancer Cells and Tumor Tissues with Carbon Nanotube Raman Tags in the Near-Infrared. 2010 , 3, 222-233	118
157	Herceptin and breast cancer: an overview for surgeons. 2010 , 19, e11-21	11
156	Mechanisms of resistance to HER family targeting antibodies. 2010 , 316, 1083-100	123
155	Highly efficient deletion of FUT8 in CHO cell lines using zinc-finger nucleases yields cells that produce completely nonfucosylated antibodies. 2010 , 106, 774-83	129
154	A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab. 2010 , 145, 84-91	16
153	The pH-dependent association with cancer cells of tunable functionalized lipid vesicles with encapsulated doxorubicin for high cell-kill selectivity. 2010 , 31, 4409-16	35
152	Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics. 2010 , 3, 7	42
151	Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients. 2010 , 103, 1331-4	6
150	Signaling through erbB receptors is a critical functional regulator in the mature cochlea. 2010 , 32, 717-24	10
149	Role of trastuzumab in the management of HER2-positive metastatic breast cancer. 2010 , 2, 93-109	6
148	Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification. 2010 , 9, 1198-207	32
147	Phase II clinical trials in oncology: are we hitting the target?. 2010 , 10, 427-38	7
146	Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. 2010 , 16, 1520-31	185
145	HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches. 2010 , 62, 150-65	60
144	Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. 2010 , 70, 4481-9	183
143	Plant-produced trastuzumab inhibits the growth of HER2 positive cancer cells. 2010 , 58, 10056-63	34

142	Increase in tissue inhibitor of metalloproteinase-2 (TIMP-2) levels and inhibition of MMP-2 activity in a metastatic breast cancer cell line by an anti-invasive small molecule SR13179. 2010 , 289, 111-8	23
141	Selective death of human breast cancer cells by lytic immunoliposomes: Correlation with their HER2 expression level. 2010 , 290, 192-203	47
140	Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations. 2010 , 12, R62	34
139	Monitoring of receptor dimerization using plasmonic coupling of gold nanoparticles. 2011 , 5, 8532-40	32
138	Growth suppression of HER2-overexpressing breast cancer cells by berberine via modulation of the HER2/PI3K/Akt signaling pathway. 2011 , 59, 8216-24	62
137	Absolute quantitation of protein therapeutics in biological matrices by enzymatic digestion and LC-MS. 2011 , 3, 2459-80	69
136	Testing for HER2 in Breast Cancer: A Continuing Evolution. 2010 , 2011, 903202	30
135	Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer. 2011 , 11, 275-82	79
134	Antibody conjugated magnetic iron oxide nanoparticles for cancer cell separation in fresh whole blood. 2011 , 32, 9758-65	275
133	Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. 2011 , 128, 347-56	353
132	Hyperspectral molecular imaging of multiple receptors using immunolabeled plasmonic nanoparticles. 2011 , 16, 116003	36
131	Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer. 2011 , 7, 187-99	22
130	p185, an immunodominant epitope, is an autoantigen mimotope. 2011 , 286, 26220-7	5
129	One target, different effects: a comparison of distinct therapeutic antibodies against the same targets. 2011 , 43, 539-49	41
128	[Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)]. 2012 , 99, 1183-91	5
127	Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector mechanisms of EGFR antibodies. 2012 , 189, 5230-9	49
126	Monoclonal antibodies at the Oncology Institute of Vojvodina: 5-year expenditure. 2012 , 20, 53-56	
125	Ductal Carcinoma In Situ: Clinical Trials Update and Resolving Controversies. 2012 , 8, 182-188	

124	New cancer immunotherapy using autologous lymphocytes activated with trastuzumab. 2012 , 35, 1213-5	5
123	Utility of the P19 suppressor of gene-silencing protein for production of therapeutic antibodies in Nicotiana expression hosts. 2012 , 10, 1118-28	59
122	Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2-extracellular domain in human cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2012 , 61, 1905-16	7.4 21
121	Optimization of immunolabeled plasmonic nanoparticles for cell surface receptor analysis. 2012 , 56, 310-6	23
120	Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor- α . 2012 , 12, 450	23
119	Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. 2012 , 10, 148	126
118	EGFR/HER-targeted therapeutics in ovarian cancer. 2012 , 4, 447-69	36
117	Trastuzumab and lapatinib modulation of HER2 tyrosine/threonine phosphorylation and cell signaling. 2012 , 29, 1486-94	8
116	Development of Antibody-Based Therapeutics. 2012 ,	5
115	Mutual Regulation of Receptor-Mediated Cell Signalling and Endocytosis: EGF Receptor System as an Example. 2012 ,	2
114	Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. 2012 , 130, 2445-54	54
113	Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. 2012 , 23, 1788-95	86
112	Targeting human epidermal growth factor receptor 2 by a cell-penetrating peptide-affibody bioconjugate. 2012 , 33, 2570-82	49
111	Comparison of HER2 immunohistochemical results using a monoclonal antibody (SV2-61) and a polyclonal antibody (for Dako HercepTest) in advanced gastric cancer. 2012 , 62, 513-7	0
110	Stability of the recombinant anti-erbB2 scFv-Fc-interleukin-2 fusion protein and its inhibition of HER2-overexpressing tumor cells. 2013 , 42, 507-16	8
109	Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance. 2013 , 13, 223-32	51
108	Enhanced cellular uptake of peptide-targeted nanoparticles through increased peptide hydrophilicity and optimized ethylene glycol peptide-linker length. 2013 , 7, 8115-27	60
107	ADVANCES IN PERSONALIZED MEDICINE. 2013 , 471-494	

106	Antibody therapeutics in cancer. 2013 , 341, 1192-8	412
105	Isolation of scFv antibody fragments against HER2 and CEA tumor antigens from combinatorial antibody libraries derived from cancer patients. 2013 , 41, 345-54	12
104	Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. 2013 , 29, 405-14	63
103	A systematic analysis of peptide linker length and liposomal polyethylene glycol coating on cellular uptake of peptide-targeted liposomes. 2013 , 7, 2935-47	137
102	scFv-based "Grababody" as a general strategy to improve recruitment of immune effector cells to antibody-targeted tumors. 2013 , 73, 2619-27	13
101	Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. 2013 , 210, 1685-93	329
100	Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3. 2013 , 34, 2031-8	20
99	Therapeutic effects of autologous lymphocytes activated with trastuzumab for xenograft mouse models of human breast cancer. 2013 , 36, 861-5	1
98	The use of lentinan for treating gastric cancer. 2013 , 13, 681-8	127
97	Deregulation of HER2 downstream signaling in breast cancer cells by a cocktail of anti-HER2 scFvs. 2013 , 20, 333-40	12
96	When Standard Therapy Fails in Breast Cancer: Current and Future Options for HER2-Positive Disease. 2013 , 3, 1000129	6
95	Advantages and Disadvantages of Targeting the C-erbB Family of Receptors in Cancer Treatment: A Review. 2014 , 06,	1
94	Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. 2014 , 20, 456-68	122
93	Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin. <i>MAbs</i> , 2014 , 6, 354-66	6.6 52
92	Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model. 2014 , 24, 1158-64	22
91	The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer. 2014 , 9, 111-22	21
90	ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab. 2015 , 15, 622	36
89	Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells. 2015 , 15, 726	10

88	Signaling Pathway of GP88 (Progranulin) in Breast Cancer Cells: Upregulation and Phosphorylation of c-myc by GP88/Progranulin in Her2-Overexpressing Breast Cancer Cells. 2015 , 9, 71-7	5
87	Selection of a novel DNA thioaptamer against HER2 structure. 2015 , 17, 647-56	16
86	Effect of lipid composition on incorporation of trastuzumab-PEG-lipid into nanoliposomes by post-insertion method: physicochemical and cellular characterization. 2016 , 26, 113-25	13
85	Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine. 2015 , 34, 504-10	11
84	Antibody Drug Conjugates: Preclinical Considerations. 2015 , 17, 525-34	31
83	A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity. 2015 , 153, 123-33	51
82	Multifunctional liposomes having target specificity, temperature-triggered release, and near-infrared fluorescence imaging for tumor-specific chemotherapy. 2015 , 216, 69-77	60
81	Immunotherapeutic approaches for cancer therapy: An updated review. 2016 , 44, 769-79	40
80	Basal Protein Expression Is Associated With Worse Outcome and Trastuzumab Resistance in HER2+ Invasive Breast Cancer. 2015 , 15, 448-457.e2	8
79	Personalized medicine: its implications and its impact on patents. 2015 , 4, 415-9	1
78	Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor α -MET Bispecific Antibody. 2015 , 290, 24689-704	28
77	Biodrug Delivery Systems. 2016 ,	4
76	. 2016 ,	4
75	Improved Aptamers for the Diagnosis and Potential Treatment of HER2-Positive Cancer. 2016 , 9,	37
74	Establishment of anti-mesothelioma monoclonal antibodies. 2016 , 9, 324	1
73	Visible to Near-Infrared Fluorescence Enhanced Cellular Imaging on Plasmonic Gold Chips. 2016 , 12, 457-65	26
72	Mechanism of Action for Therapeutic Antibodies. 2016 , 85-111	2
71	DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. 2016 , 22, 5097-5108	308

70	A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells. 2016 , 6, 32		17
69	Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results. 2016 , 155, 273-84		22
68	bisFabs: Tools for rapidly screening hybridoma IgGs for their activities as bispecific antibodies. <i>MABs</i> , 2017 , 9, 430-437	6.6	10
67	Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis. 2017 , 164, 581-591		37
66	Developments in therapy with monoclonal antibodies and related proteins. 2017 , 17, 220-232		91
65	Lipid and Membrane Structures. 2017 , 139-182		1
64	Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses. <i>MABs</i> , 2018 , 10, 547-571	6.6	24
63	Mechanisms of Action and Resistance of Trastuzumab in Breast Cancer. 2018 , 51-66		
62	Whole exome sequencing to identify genetic markers for trastuzumab-induced cardiotoxicity. 2018 , 109, 446-452		21
61	Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer. 2018 , 35, 95		13
60	Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. 2018 , 200, 565-572		18
59	Receptor Tyrosine Kinase-Targeted Cancer Therapy. 2018 , 19,		103
58	The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2. 2018 , 18, 238		19
57	Biomarker-Driven Drug Discovery in Cancer-Trastuzumab Development: 2019 Lasker-DeBakey Clinical Medical Research Award. 2019 , 322, 1249-1250		1
56	Harnessing the Immune System in HER2+ Disease. 2019 , 213-230		
55	Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer. 2019 , 9, 1583		27
54	Clinicopathological values of PD-L1 expression in HER2-positive breast cancer. 2019 , 9, 16662		21
53	Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors. 2019 , 83, 329-340		10

52	Characterizing Trastuzumab-Induced Alterations in Intratumoral Heterogeneity with Quantitative Imaging and Immunohistochemistry in HER2+ Breast Cancer. 2019 , 21, 17-29	13
51	Pathology, Biomarkers, and Molecular Diagnostics. 2020 , 225-253.e8	3
50	Improving Receptor-Mediated Intracellular Access and Accumulation of Antibody Therapeutics-The Tale of HER2. 2020 , 9,	6
49	An efficient and precise method for generating knockout cell lines based on CRISPR-Cas9 system. 2020 , 20, 585-593	1
48	In vivo modeling of the EGFR family in breast cancer progression and therapeutic approaches. 2020 , 147, 189-228	2
47	NK Cells in Immunotherapy: How Important Are They?. 2021 , 65-81	
46	Quantitative Determination of Intracellular Bond Cleavage. 2021 , 305-330	0
45	The SHREAD gene therapy platform for paracrine delivery improves tumor localization and intratumoral effects of a clinical antibody. 2021 , 118,	2
44	Non-fucosylated Therapeutic Antibodies: The Next Generation of Therapeutic Antibodies. 2008 , 1-9	1
43	Towards an immunotherapy for p185HER2 overexpressing tumors. 1994 , 353, 83-94	2
42	Tumorinvasion Die Rolle der Rezeptoren. 1995 , 17-27	1
41	Targeting of sterically stabilized liposomes to cancers overexpressing HER2/neu proto-oncogene. 1998 , 325-345	2
40	Monoclonal antibody therapy for breast cancer: herceptin. 2003 , 21, 223-33	31
39	Signal-transduction therapy. A novel approach to disease management. 1994 , 226, 1-13	140
38	Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. 2008 , 118, 3574-81	84
37	Herceptin conjugates linked by EDC boost direct tumor cell death via programmed tumor cell necrosis. 2011 , 6, e23270	6
36	Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer. 2015 , 6, 12436-51	16
35	Effect of blocking IGF-I receptor on growth of human hepatocellular carcinoma cells. 2006 , 12, 3977-82	22

34	Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing. 2008 , 132, 1008-15		44
33	A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial). 2021 , 158, 169-180		2
32	Antibody-Targeted Gene Therapy. 2002 , 81-94		
31	The importance of antibody dependent cell-mediated cytotoxicity (ADCC) for breast cancer response to trastuzumab - Herceptin. 2002 , 10, 162-163		
30	The Rise of Antibodies as Therapeutics. 2002 , 427-469		
29	Tiermodelle in der biomedizinischen Forschung. 2003 , 299-339		
28	Recombinant proteins and genomics in cancer therapy. 2003 , 59-92		
27	Treatment with Monoclonal Antibodies. 2004 , 529-568		
26	Antibody-Mediated Drug Delivery in Cancer Therapy. 2004 , 311-344		
25	Trastuzumab. 2007 , 1-5		1
24	Recombinant proteins and genomics in cancer therapy. 2009 , 53-83		
23	Trastuzumab??????????????????????????????????????. <i>Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)</i> , 2011 , 36, 163-168	0	1
22	Preclinical Considerations for Development of Antibody-Based Therapeutics in Oncology. 2012 , 183-240		
21	Role of Stroma in Disease Progression. 2013 , 129-147		
20	Monoclonal Antibodies. <i>Cancer Drug Discovery and Development</i> , 2014 , 585-624		0.3
19	Pathology, Biomarkers, and Molecular Diagnostics. 2014 , 226-252.e6		
18	Signal-transduction therapy. 1994 , 195-207		
17	HER-2/neu as a predictive marker of response to breast cancer therapy. 1998 , 155-167		

16	Recombinant Organisms as Source of Cancer Biotherapeutics. 1998 , 51-77		
15	Sterically Stabilized Immunoliposomes: Formulations for Delivery of Drugs and Genes to Tumor Cells in Vivo. 1998 , 41-47		
14	HER-2/neu in Breast Cancer: A Possible Means of Therapy?. 1998 , 121-136		
13	Breast Cancer Therapy Using Monoclonal Antibodies Against Epidermal Growth Factor Receptor and HER-2. 1999 , 419-436		
12	Peptide-Based Cancer Vaccines and Therapeutics for Solid Tumors Overexpressing HER-1, HER-2, HER-3, VEGF and IGF-1R. 2017 , 1-31		
11	Tiermodelle in der biomedizinischen Forschung. 2008 , 207-241		
10	Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC. <i>Drug Design, Development and Therapy</i> , 2009 , 3, 7-16	4.4	77
9	Vaccination against Her-2/neu, with focus on peptide-based vaccines.. <i>ESMO Open</i> , 2022 , 7, 100361	6	1
8	Trastuzumab (Herceptin) in the treatment of breast cancer with HER2 overexpression. 2001 , 3, 172-182		1
7	Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings.. <i>Npj Breast Cancer</i> , 2022 , 8, 32	7.8	1
6	CLEC5a-directed bispecific antibody for effective cellular phagocytosis.. <i>MABs</i> , 2022 , 14, 2040083	6.6	
5	Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies. 13,		2
4	Squalamines in Blockade of Tumor-Associated Angiogenesis and Cancer Progression. 2022 , 14, 5154		0
3	Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers. 2023 , 175, 101-111		0
2	MULTIMODALITY TESTING OF HER2/NEU MARKER IN BREAST CANCER: A CORRELATIVE STUDY. 1413-1443		0
1	An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. 2023 , 14,		0